Slides
Page 1
Investor Presentation Galenica Group August 2026 0000 Galenica
Page 2
Investor Presentation Galenica Group Table of contents About Galenica page 03 Market environment page 27 Business performance page 37 Governance page 56 Sustainability page 67 Outlook page 76 August 2026 2
Page 3
About Galenica
Page 4
Investor Presentation Galenica Group 35% 65% Net sales1 Galenica Group Products & Care Logistics & IT Galenica in figures August 2026 4 74% 26% EBIT adjusted1,2 Galenica Group Products & Care Logistics & IT Leading healthcare provider in Switzerland 381 own pharmacies Employees (Headcount) > 8,400 Dividend yield1 2.6% CHF 4,135.6 million CHF 234.8 million 1 Figures as of 31 December 2025 2 EBIT adjusted, without effects of IAS 19, IFRS 16, IFRS3 and one -off effects see chapter “Alternative performance measures” of the Annual Report 2025
Page 5
Investor Presentation Galenica Group Building the leading Swiss healthcare platform Umsatz +10.2% EBIT +26.4% Joint Venture Opening of highly automated distribution centre in Niederbipp Acquisition Organic and acquisition-led expansion of pharmacies network Acquisition Creation of Amavita uniform brand in Switzerland Acquisition Segment Products & Care 2000 20092002 2005 2007 2008 Segment Logistics & IT 2013 Acquisition Acquisition 2017 Acquisition IPO August 2026 5
Page 6
Investor Presentation Galenica Group Building the leading Swiss healthcare platform 20222018 2019 2020 2021 Acquisition Acquisition Relaunch Acquisition AcquisitionAcquisition Acquisition Joint Venture Strategic partnership Acquisition Acquisition 2023 Acquisition Joint Venture Strategic partnership 2024 Participation Participation Segment Products & Care Segment Logistics & IT Strategic partnership August 2026 6 2025 Acquisition
Page 7
Investor Presentation Galenica Group Switzerland‘s leading fully integrated healthcare provider Largest network of pharmacies in Switzerland with over 500 pharmacies, online and offline. Well-known brands and products and exclusive licensed products from business partners. Wide range of home care services for patients and professional service providers. 7 Innovative Swiss diagnostics service provider with highly efficient Core Lab. Leading pharma logistics provider in the healthcare sector. Development of IT solutions for the digitization of the Swiss Healthcare sector. August 2026
Page 8
Vision Activation There for you every day. #StrongTogether Strategy Added value in the network We generate value for customers and partners Omni-Channel Health Services & Products Strategy Shaping the future We are shaping the healthcare of tomorrow Digital Health Connecting Healthcare Values Sustainably successful We work efficiently and effectively Efficiency Sustainability (ESG) Pioneers in transition We rethink and move forward together Transformation Employer of choice
Page 9
The Galenica network
Page 10
Investor Presentation Galenica Group Our business areas Products & Care1 Logistics & IT 1 Pharmacies Omni-Channel Products & Brands Services & Production Diagnostics Wholesale Logistics & IT Services 1,473m CHF 194m CHF 120m CHF 41m CHF 3,255m CHF Net sales 1,816m CHF EBIT2 175m CHF Net sales 3,333m CHF EBIT 2 62m CHF 1 Figures as of 31 December 2025 2 EBIT adjusted, without effects of IAS 19, IFRS 16, IFRS3 and one -off effects see chapter “Alternative performance measures” of the Annual Report 2025 Net sales Net salesNet sales Net sales Net sales Net sales 80m CHF August 2026 10
Page 11
Investor Presentation Galenica GroupAugust 2026 11 New revenue segmentation 2025 Galenica revised revenue reporting to reflect organizational changes and increase transparency Previously Logistics & IT Wholesale Logistics & IT Services Products & Care Retail (B2C) Local Pharmacies Pharmacies at Home Professionals (B2B) Products & Brands Services for Professionals Pharma Internal Services Products & Care New Pharmacies Omni-Channel Products & Brands Services & Production Services & Diagnostics Logistics & IT Wholesale Logistics & IT ServicesInternal Services
Page 12
Investor Presentation Galenica Group Pharmacies Omni-Channel Three largest pharmacy chains in Switzerland Key takeaways − Largest pharmacy network offers broad product range, including well-known own brands, as well as health services and tests − Built organically and through targeted acquisitions since 2000 − Including attractive, high customer traffic locations across Switzerland. − Multi-brand strategy: pharmacies formats include different store concepts and product ranges to respond to different customer needs. − Market share of ~25% in terms of sales − Own customer loyalty programme Starcard (Amavita), SunCard (Sunstore) and Coop Supercard (Coop Vitality) Largest branded pharmacy network by number of pharmacies in Switzerland 1 209 The first Swiss pharmacy chain 87 Joint venture (49:51) with Coop, the 2nd largest retail group in Switzerland 87 1 Amavita figures include 6 majority holdings in other pharmacies, figures as of 30 June 2026 August 2026 12
Page 13
Investor Presentation Galenica Group 39% 16%6% 13% 19% 7% Amavita and Sun Store product offering in % of sales1 Pharmacies Omni-Channel Broad range of product and service offerings 1 Share of net sales Dec 2025 YTD by product category generated by local pharmacies Prescription medicines of which originals of which generics of which service fees OTC medicines Nutrition, Personal and Patient Care Beauty61% Service offerings in local pharmacies (selection) Health Checks COVID-19 Tests and VaccinationsVaccinations OnlineDoctor Primary Care August 2026 13
Page 14
Investor Presentation Galenica Group Pharmacies Omni-Channel Always available where our customers are Widely spread pharmacy network covers every Region in Switzerland Demonstrated M&A track record with an average of 8 pharmacies acquired and 3 net pharmacies added per year over the last 5 years 2022 2023 2024 2025 H1 26 Pharmacies acquired 4 7 12 9 5 New pharmacies opened 3 1 3 1 1 Pharmacies closed -7 -7 -8 -5 -3 Total own2 Pharmacies 368 369 376 381 384 3812 100 76 Galenica No 2 No 3Network of chains Number of pharmacies as of 31 Dezember 2025 (Total 1,830 pharmacies in Switzerland 1) ~4x more pharmacies than next competitor 1 Based on number of pharmacies. Source: pharmaSuisse 2025, Fakten und Zahlen Schweizer Apotheken 2 Own includes 88 pharmacies through joint venture with Coop as well as MediService August 2026 14
Page 15
Investor Presentation Galenica Group Strategic JV with Redcare Pharmacy N.V. The Redcare JV offers compelling long-term upside exposure to the fast-growing Swiss online pharmacy market. Market leading online and mail-order1 pharmacy in Switzerland The business activities of MediService and redcare-apotheke.ch are combined in the joint venture: − MediService customers are benefiting unchanged from the comprehensive range of products and services, supplemented with the offers and services of redcare-apotheke.ch. − The customers of redcare-apotheke.ch are given easy access to MediService's comprehensive range of prescription drugs and home care services. MediService as a specialty pharmacy continues to focus on patients with chronic illnesses as well as need for home care services: − Constantly expanding services, moving from a highly specialised mail-order pharmacy to a Distance Healthcare Provider − Active in over 60 specialty indications, especially in neurology, immunology, rare diseases and oncology 1 IQVIA, Pharmaceutical Market Switzerland, YTD December 2025, Rx market Switzerland by channels, market leading mail-order pharmacy in terms of net sales 40% 50% 60% 70% Market Share Mail-order pharmacies1 Mediservice Other mail-order pharmacies August 2026 15
Page 16
Investor Presentation Galenica Group Products & Brands Strong brands for the Swiss Consumer Healthcare Market Selected own brandsKey takeaways − Leading position1 in the Swiss consumer healthcare market (CHC) − Preferred Consumer Health partner for Swiss Pharmacies & Drugstores − Broad Sales & Training force − Expanding portfolio of own and exclusive partner brands − Leveraging of Galenica’s Retail platform to distribute Verfora & Partner brands Distribution partner of choice − Continued growth strategy for big OTC brands, complementary medicine, beauty and Rx − Build-up of physician field service Selected partner brands 1 Based on IQVIA Sell-out Street Price Pharmacies & Drugstores December 2025 August 2026 16
Page 17
Investor Presentation Galenica Group Products & Brands Strong brands for the Swiss Consumer Healthcare Market Verfora market share in Swiss CHC market1 in 2025 OTC products 14.3% market share CHF 245.0 million Personal care 6.3% market share CHF 31.8 million Patient Care 1.2% market share CHF 3.9 million Nutrition 0.3% market share CHF 0.2 million 10.7% CHF 280.8 million Pain relief 28.8% (CHF 74.0 million) Vitamins, minerals & nutritional supplements 5.9% (CHF 17.0 million) Cough & cold 19.5% (CHF 70.5 million) Digestive system 13.4% (CHF 26.4 million) Market share of main OTC product categories of Verfora1 1 Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland (Dec 2025), streetprices, figures include Padma and Spagyros products August 2026 17
Page 18
Investor Presentation Galenica Group 4.0% 6.0% 8.0% 10.0% 2017 2018 2019 2020 2021 2022 2023 2024 2025 Products & Brands Proven M&A track record as key driver for market share growth 18 Acquisition Padma® Distribution Allergosan® Acquisition Hedoga Group Distribution Bucco-Tantum ® Distribution ThermaCare ® Distribution Uriage ® Acquisition Merfen ® and Vita-Merfen® Distribution Mustela ® Distribution Lierac and Phyto Launch Distribution Vicks and Metamucil Distribution Excilor Distribution Oenobiol OTC Beauty Complementary Medicine Distribution Boiron® Acquisition Spagyros ® Market share August 2026 Distribution Cooper Consumer Health ® Acquisition Dr. Wild
Page 19
Investor Presentation Galenica Group Services & Production We support healthcare professionals with high quality services • Bichsel delivers specialized home care services for care organizations, across Switzerland and delivers product-neutral, patient-centric care nationwide. • Reducing nursing staff burden through digital solutions and specialist expertise Galenica. • Lifestage Solutions develops and operates a fully integrated digital trading platform for home care organizations and nursing homes • Strong customer focus: the platform simplifies daily workflows for its customers using digitalization and state-of-the-art technology Pharmacies Nursing homes / Homecare organisations • Prepared drugs in blisters ensuring safe medication • Key customers include nursing homes August 2026 19
Page 20
Investor Presentation Galenica Group Services & Production - Homecare One digital platform for home care services Care materials (MiGeL) and billing Artificial nutrition and parenteral therapies Home doctors Patientenindividuelle Verblisterung von Medikamenten Regional pharmacies Patient-specific blister packaging of medicines Overview of services Galenica’s comprehensive range of services relieves the burden on specialists and optimises work processes August 2026 20
Page 21
Investor Presentation Galenica GroupAugust 2026 21 Diagnostics Galenica operates fourth largest lab in Switzerland 70% of all diagnoses are based on lab analyses Established player with deep market knowledge Significant previous investments in innovation, infrastructure & digitalisation Strong foundation for growth with Galenica
Page 22
Investor Presentation Galenica Group Wholesale Leader in wholesale distribution Key takeaways − Wide product range with around 100,000 products in pharma, non-pharma, practice & laboratory equipment and medical devices, whereof around 50% in stock − Integrated services, high quality standards − Ensuring the basic drug supply in Switzerland − Main site at Niederbipp operates at up to 60% automation − GDP3-compliant services − > 1,000 suppliers 31% 37% 32% Wholesale market share1 % physician channel Galenica Other Wholesalers Direct 25% 24% 51% Wholesale market share1 % pharmacy channel Galenica (to own pharmacies) Galenica (to third pharmacies) Others 1 Galenica: based on market share. Source: IQVIA Pharmacy and Physician Market December 2025; Galenica internal sales split bas ed on company information 2 Prescription products 3 Good Distribution Practice August 2026 22
Page 23
Investor Presentation Galenica Group Wholesale Leader in wholesale distribution Pharmacies ~ 1,300 Hospitals/Nursing homes > 570 Drugstore ~ 300 Medical practices > 5,600 Wholesale distribution with four distribution centers Customers by channel August 2026 23
Page 24
Investor Presentation Galenica Group Logistics & IT Services Leader in pre-wholesale distribution 47% 38% 9% Alloga No. 2 No. 3 Key takeaways − Third-party logistics provider for the pharmaceutical industry (pre-wholesaling) including additional services (labeling, repacking, clinical trial service, PharmaServices, Contact Center as a Service) − Service quality as key differentiator − GDP (Good Distribution Practice) − GMP (Good Manufacturing Practice) − Temperature zones: 15-25⁰C, 2-8⁰C, -20⁰C, -80⁰C Warehouse capacity 37,900 m2 Stock items (SKU) > 12,000 Pharma partners > 100 Shipping parcels and pallets per year ~ 600,000 Pre-wholesale market share1 1 Company estimate August 2026 24
Page 25
Investor Presentation Galenica Group Logistics & IT Services Our approach towards more patient safety, convenience and efficiency Medication Master Data August 2026 25 Patients on-/offline Diagnosis Clinical Decision Support (CDS.CE) (medication and vaccination) Prescription E-Prescription Therapy e-Mediplan Anamnesis
Page 26
Investor Presentation Galenica Group Strategic partnerships Galenica as preferred partner in Swiss Healthcare Pharmacies Logistics Health Insurances Digital Platforms eHealth Solutions - JV with Coop (leading Swiss Mass Retailer) - JV with Redcare Pharmacy (leading European online pharmacies) - 202 independent partner pharmacies at Winconcept - JV with Planzer (leading Swiss logistics provider) for sustainable transport solutions - Basic insurance models - Supplementary insurance models - Presence on the Swiss health platforms Well and Benecura (together with other major players in Swiss Health Care) - IT and data services of HCI such as clinical decision support (CDS) are integrated in all relevant Health Care Systems in Switzerland Product distribution - Verfora is preferred distribution partner for products in Swiss pharmacy channel Strategic partnerships August 2026 26
Page 27
Market environment
Page 28
Investor Presentation Galenica Group Swiss healthcare market Proven track record of resilient and stable growth Development of Swiss healthcare retail sector1 in billion CHF (based on ex-manufacturer price) August 2026 28 3.9 4.1 4.2 4.4 4.4 4.5 4.6 4.9 5.3 5.6 5.8 6.1 6.4 6.6 6.9 0 1 2 3 4 5 6 7 8 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025E 2026E 2027E 2028E 2014-25 CAGR 4.2% 2025-28 CAGR 4%2 − Underlying healthcare sector growth drivers, including demographics, lifestyle and innovation − One of the highest life expectancy rates in the world − Non-discretionary nature of products and services 1 IQVIA, Pharmaceutical Market Switzerland, YTD December 2025, total market without hospitals 2 Company estimate
Page 29
Investor Presentation Galenica Group Drugstores CHF 29.0 million (-2.9%) 2.7 million packs (-4.3%) Swiss pharmaceutical market June 2026 29 43.6% 5.2% 26.8% 0.7% 23.6% Physicians CHF 1,092.4 million (+3.1%) 22.8 million packs (-0.1%) Hospitals CHF 962.4 million (+0.2%) 7.7 million packs (+1.2%) Local Pharmacies CHF 1,777.6 million (+5.4%) 65.0 million packs (-0.7%) Total market growth CHF 4,074.7 million (+3.7%) 99.1 million packs (-0.6%) Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA – Swiss pharmaceutical market June 2026 Mail-order Pharmacies CHF 213.3 million (+11.2%) 0.8 million packs (-8.3%) August 2026
Page 30
Investor Presentation Galenica Group Swiss pharmaceutical market 30 500 520 540 560 580 600 620 640 660 680 700 720 740 760 Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez 2024 2025 2026 Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA – Swiss pharmaceutical market June 2026 in million CHF August 2026
Page 31
Investor Presentation Galenica Group 6% 21% 23% 34% 16% Drugs reimbursable by health insurance in Swiss pharmacy channel June 2026 YTD (by packs) Swiss pharmaceutical market Galenica as key driver of generic substitution in Switzerland 44.6 million packs Market with generics 22.2 million Market with generics potential 32.5 million Substitution rate Pharmacies Galenica Group 3 79.6% Patent protected products 2.7 million, +9.1% Generics/Biosimilars 15.3 million, +3.7% Others2 9.3 million, +3.4% Pharmacies sales HY 26 growth with generics +6.4%Products with expired patent protection without generics 10.3 million, -3.8% Originals/Reference products1 6.9 million, -1.7% Source: IQVIA Switzerland - Swiss pharmaceutical market 2025, Market Segmentation, reimbursable products (FOPH) in the pharmacy channel. Monthly calculation basis, delineated market division, data as of June 2026 YTD 1 Products with expired patent protection and at least one generic or biosimilar 2 1. Natural substance (e.g. vitamins, minerals, herbal ingredients); 2. Vaccines; 3 Source: Galenica Group August 2026 31
Page 32
Investor Presentation Galenica Group 29.9% 33.0% 33.6% 34.3% 18.2% 15.4% 15.5% 15.5% 6.2% 6.0% 5.9% 6.1% 45.8% 45.6% 45.0% 44.1% Dec 23 Dec 24 Dec 25 June 26 18.5% 21.0% 21.1% 20.4% 16.2% 12.6% 11.8% 11.5% 46.1% 46.1% 47.1% 48.4% 19.2% 20.3% 20.0% 19.7% Dec 23 Dec 24 Dec 25 June 26 Swiss pharmacy market by drug category Generic penetration largely stable in H1 2026 32 Swiss Pharmacy Channel (Split by value) Swiss Pharmacy Channel (Split by volume) Products with expired patent protection without generics / out of market / others 2 Originals/reference products 1 August 2026 Patent protected products Generics / Biosimilars Source: IQVIA Switzerland - Swiss pharmaceutical market 2023 -2026, Market Segmentation, reimbursable products (FOPH) in the pharmacy channel. Monthly calculation basis, delineated market division, data as of Dec 2 023/2024/2025 and Jun 2026 1 Products with expired patent protection and at least one generic/biosimilar 2 1. Natural substance (e.g. vitamins, minerals, herbal ingredients); 2. Vaccines
Page 33
Investor Presentation Galenica Group Consumer healthcare market June 2026 65.1% 19.4% 12.7% 2.8% OTC 0.0% Personal care -1.1% Patient care +2.7% Nutrition +1.2% 33 Total market CHF 1,310.0 million +0.2% Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices © IQVIA – Consumer Health market June 2026 Non-medication segment +0.5% August 2026
Page 34
Investor Presentation Galenica Group Swiss healthcare market: regulatory environment Topic/Initiative Current status Reduction in drug prices − Standard process, FOPH verifies drug prices in a three-year cycle OTC products:1 online trade − Federal Council presented a proposal, consultation starting most probably in 2026 − Implementation of a new law at earliest in 2029 TransAL2 and TarDoc in lab business − Replaced 2026 the outdated TARMED. Combines a new individual service tariff with ambulatory flat-rate packages. Expected to be cost neutral for Diagnostics business. − As part of the FOPH's 2026 cost-containment package, effective H2 2026, the handling fee has been cut by CHF 5, alongside a 10% price reduction on the ten highest-revenue lab tests. This is partially offset by Tardoc, where electronic order capture is already remunerated,cushioning the net impact of the price cuts. Revision MiGeL remuneration in Services & Production business − Ongoing incremental revisions regarding artificial nutrition reimbursement. 1 Swissmedic category D August 2026 34
Page 35
Investor Presentation Galenica Group Swiss healthcare market: regulatory environment Constant pressure on drug prices Annual savings per channel due to price cuts of SL products at public and ex-factory price in million CHF 38 32 62 52 35 28 85 72 64 50 29 25 28 24 24 20 23 19 47 41 27 20 21 19 34 32 12 11 21 19 31 30 13 11 13 12 0 20 40 60 80 100 120 140 160 180 200 Public price Ex-factory price Public price Ex-factory price Public price Ex-factory price Public price Ex-factory price Public price Ex-factory price Public price Ex-factory price Pharmacies Physicians Hospitals Analysis FOPH price reductions 2025 – Source: IQVIA APO/SD/SPI SL products, based on input FOPH 2020 2021 2022 2024 Drug prices reviewed in three-year cycles 2023 August 2026 35 2025 prov.
Page 36
Investor Presentation Galenica Group Swiss healthcare market: regulatory environment Concept of distribution margin (valid since 1 July 2024) FOPH defines price and margin – Margin covers wholesale and retail Ex factory price (in CHF) + price- related surcharge + surcharge per pack 0.05-7.99 6.0% 9.00 8.00-4’601 6.0% 16.00 From 4’601 - 300.00 In addition, the updated distribution margin includes a uniform margin for medications with the same active ingredient composition (lowest margin). Thanks to its high generic substitution rate of ~80%, the impact of the new distribution margin to Galenica was neutral.Public price Ex factory price 5 10 15 20 25 30 35 40 70 60 50 40 30 20 10 Ex factory price (in CHF) + price- related surcharge + surcharge per pack 0.05-4.99 12.0% 4.00 5.00-10.99 12.0% 8.00 11.00-14.99 12.0% 12.00 15.00-879.99 12.0% 16.00 880.00- 2’569.99 7.0% 60.00 From 2’570.00 - 240.00 Old model Current model Old model (until 30 Jun 2024) Current model (since 1 Jul 2024) August 2026 36
Page 37
Business performance Our success story
Page 38
Investor Presentation Galenica Group Performance overview Galenica Group History of resilient growth and margin improvement 2,826 2,915 3,009 3,141 3,165 3,301 3,480 3,8352 4,014 3,7463 3,921 4,1364 0.0% 3.0% 6.0% 0 1’000 2’000 3’000 4’000 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2014 – 2022 including MediService (incl. discontinued operations) CAGRs Galenica net sales 4.5% Galenica EBIT 1 7.0% Source: Company information, Galenica Annual Reports, IQVIA 1 2014-16 reported EBIT, 2017-2024 adjusted EBIT (excluding IAS 19 impact and effects of IFRS 16 leasing (since 2019)), 2025 see c hapter “Alternative performance measures” of the Annual Report 2025 2 EBIT margin influenced by positive impact from COVID -19 initiatives of CHF 25 million and profit from property sale of CHF 9.4 m illion 3 EBIT margin influenced by one-off expenses (net) of CHF 9.8 million 4 EBIT margin positively influenced by reimbursement ComCo of 6.2 million Net sales (CHFm) EBIT margin % 2023-2025 w/o MediService (continuing operations) CAGRs Galenica net sales 5.1% Galenica EBIT 3, 4 10.8% August 2026 38
Page 39
Investor Presentation Galenica Group Performance overview Galenica Group Strong performance development in both segments August 2026 39 80 89 93 100 110 124 124 1553 154 1524,5 1604,7 175 9.6% 0% 5% 10% 15% 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Products & Care Logistics & IT Source: Company information, Galenica Annual Reports 1 2014-16 reported EBIT, 2017-2024 adjusted EBIT (excluding IAS 19 impact and effects of IFRS 16 leasing (since 2019)), 2025 see c hapter “Alternative performance measures” of the Annual Report 2025 2 2017 including one-off effects (CHFm7.0), comparable EBIT CHFm 43.6 and ROS 1.8% 3 Products & Care: Including positive Impact from COVID -19 of CHF 19 million / Logistics & IT: Including positive Impact from COVI D-19 of CHF 6 million and profit from property sale of CHF 9.4 million 4 Numbers excluding MediService (discontinued operations), figures 2014 -2022 are as reported (including MediService) 5 Products & Care: EBIT 2023 positively influenced by one -off effect of CHF 3.0 million, comparable EBIT of CHF 149 million and RO S 9.1% 6 Logistics & IT: EBIT 2023 negatively influenced by one -off effect of CHF 12.8 million, comparable EBIT of CHF 55 million and ROS 1.8% 7 Reallocation of internal IT services from the Logistics & IT segment to Group Services 8 Logistics & IT: EBIT positively influenced by reimbursement ComCo of 6.2 million EBIT margin % 2,171 2,245 2,329 2,362 2,372 2,441 2,625 2,831 2,933 3,077 3,1807 3,333 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 36 36 40 51 2 44 45 45 61 3 49 42 6 54 7 62 8 1.9% 0% 5% 10% 15% 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1,335 1,393 1,437 1,479 1,525 1,621 1,683 1,908 2,030 1,6364 1,7004 1,8164 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 8.5% EBIT adjusted1 (CHFm) Net sales (CHFm) 5.4% 4.0% 5.0% CAGRs 5.4% 7.3%
Page 40
Investor Presentation Galenica Group 1,995 867 1,618 2,136 967 1,685 Galenica Group Products & Care Logistics & IT H1 2025 H1 2026 Galenica Group Strong sales growth supported by acquisition of Labor Team +7.1%Net sales (in million CHF) +11.5% +4.2% 40August 2026 Growth w/o Labor Team +4.0% +4.3% +4.2%
Page 41
Investor Presentation Galenica Group Net sales (in million CHF) H1 2025 H1 2026 change Pharmacies Omni-Channel 713.0 756.9 +6.2% Products & Brands 101.1 91.2 -9.8% Services & Production 57.9 63.4 +9.4% Diagnostics 0.0 62.2 Products & Care 867.3 967.2 +11.5% Wholesale 1’579.6 1’647.3 +4.3% Logistics & IT Services 39.2 38.9 -0.8% Logistics & IT 1’617.6 1’684.9 +4.2% Galenica Group 1’995.4 2’136.5 +7.1% Galenica Group Strong sales growth in both segments August 2026 41
Page 42
Investor Presentation Galenica Group 1,473 713 757 2025 H1 2025 H1 2026 Pharmacies Omni-Channel Growth driven by prescription medicines and acquisitions 42 Net sales (in million CHF) +6.2% August 2026 Expansion impact1 of +1.9% due to acquisition of majority stake in puravita, portfolio of local pharmacies expanded by 3 locations Generics substitution rate remains with 79.6% at high level (78.1% at Dec 2025). 1) The effect of net expansion is calculated only including point of sales and business activities without a full year period co mparison (acquisitions, openings and closure of pharmacies)
Page 43
Investor Presentation Galenica Group 158 80 76 36 21 15 194 101 91 2025 H1 2025 H1 2026 Products & Brands Seasonal effects burden sales development 43 Net sales (in million CHF) -9.8% Swiss market International -5.1% -27.8% August 2026 Swiss market: − Growth of CH market sales1 -2.6% − Market share1 of 10.5% 1) Product sales to end customers of Verfora, Spagyros and Padma products (like -for-like, streetprices), IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, Consumer Health market YTD June 2026
Page 44
Investor Presentation Galenica Group 120 58 63 2025 H1 2025 H1 2026 Services & Production Strong sales growth in homecare business 44 Net sales (in million CHF) August 2026 +9.4% Consistent, strong growth with services for homecare organizations and nursing homes
Page 45
Investor Presentation Galenica Group 185 92 90 2,136 1’027 1’092 934 461 465 3,255 1,580 1,647 2025 H1 2025 H1 2026 Wholesale Further market share gains in pharmacies segments 45 Net sales (in million CHF) -2.0% +4.3% Pharmacies Physicians Others +1.0% +6.3% August 2026
Page 46
Investor Presentation Galenica Group 80 39 39 2025 H1 2025 H1 2026 Logistics & IT Services Stable development with Prewholesale and IT services 46 Net sales (in million CHF) August 2026 -0.8%
Page 47
Investor Presentation Galenica Group 81.0 81.0 93.3 30.2 -5.4 24.8 25.3 109.9 104.5 117.7 H1 2025 one-off items H1 2025 w/o one-off H1 2026 47 Strong EBIT growth excluding prior-year one-off effects EBIT adjusted1) (in million CHF) ROS (in %) 1 without effects of IAS 19, IFRS 16, IFRS3 and one-off effects, see chapter “Alternative performance measures” of the Half year report 2026 2 One-off effects of CHF 5.4 million relate to a new legal assessment of the ComCo sanction involving HCI and Markant. 3 Restated: reallocation of internal IT services from the Logistics & IT segment to Group Services 2 1.9% 9.3% 9.3% 9.6% 1.5% 1.5% Logistics & IT Products & Care +15.2% +2.0% August 2026 +12.6% 3
Page 48
Investor Presentation Galenica Group Grossmargin in % net sales H1 2025 H1 2026 H1/H1 VJ Galenica Gruppe 27.6% 28.7% 1.0% Products & Care 46.3% 47.5% 1.2% Logistics& IT 9.3% 9.0% -0.2% Gross margin & Personnel cost Overall improvement of gross margin 48August 2026 Grossmargin: − Pharmacies margins are under pressure from a higher Rx mix, while Diagnostics margins are accretive − Logistics slightly impacted by an unfavourable product mix. Personnel cost: − Strict personnel cost discipline across pharmacies and efficiency gains in Pre- wholesale, neutralised by the Labor Team acquisition and its different personnel cost structure. Personalkosten in % net sales H1 2025 H1 2026 H1/H1 VJ Galenica Gruppe 15.1% 15.5% 0.3% Products&Care 22.4% 22.8% 0.4% Logistics & IT 4.0% 3.9% -0.1%
Page 49
Investor Presentation Galenica GroupAugust 2026 1 without effects of IAS 19, IFRS 16, IFRS3 and one-off effects, see chapter “Alternative performance measures” of the Annual Report 2025 49 D&A : Increase due to go-live of Wholesale ERP system in Ecublens Financial Results: Decline compared to the prior year, mainly reflecting lower positive remeasurement effects on contingent consideration liabilities Adjusted Net Profit & Loss Statement1 in million CHF H1 2025 H1 2026 in % Net sales 1’995 2’136 +7.1% Other income 9 7 -19.9% Cost of goods -1’445 -1’524 +5.5% Personnel costs -302 -331 +9.5% Other OPEX -122 -142 +16.2% Share of profit from JV 3 5 +56.5% EBITDA 138 151 +9.4% D&A -28 -34 +18.3% EBIT 110 118 +7.1% ROS 5.5% 5.5% Financial result -1 -7 +642.8% Taxes -18 -19 +5.2% Tax rate 16.8% 17.3% Net profit 91 92 +1.3%
Page 50
Investor Presentation Galenica Group 1,509 1,465 1,443 675 533 837 2025 H1 2025 H1 2026 50 Balance sheet Debt coverage shift driven by seasonal WC build Debt coverage adjusted2 in million CHF Net debt adjusted1 Equity adjusted1 2.3x 1 Detail of the adjustments in the Half year report 2026, see chapter “Alternative performance measures” 2 See chapter “Alternative performance measures” of the Half year report 2026 1.9x August 2026 2.7x
Page 51
Investor Presentation Galenica Group Condensed balance sheet August 2026 51 Trade receivables and current liabilities: Increase, mainly reflecting seasonal working capital effects and ERP migration preparations. Shareholders’ equity: Reduction reflecting the dividend payout. in million CHF Dec 2025 Jun 2026 Change Cash and cash equivalents 116 40 -76 Trade and other receivables 527 630 +103 Inventories 385 396 +11 Other assets 581 573 -8 Property, plant and equipment 274 256 -19 Intangible assets 1’414 1’430 +16 Total assets 3’297 3’324 +27 Current financial liabilities 215 293 +78 Other current liabilities 718 750 +32 Non-current financial liabilities 602 604 +3 Other non-current liabilities 278 263 -15 Shareholder's equity 1’485 1’415 -70 Total liabilities & shareholder's equity 3’297 3’324 +27
Page 52
Investor Presentation Galenica Group Cash Flow Statement 52August 2026 1 Reduced by payment of lease liabilities IFRS16, see chapter “Alternative performance measures” of the Annual report 2025 2 Net cash flow from business combinations and net cash flow from sale of subsidiaries Operating cash flow: Higher working capital driven by seasonal effects, delayed invoicing and ERP migration preparations Capex: Low H1 2026 investments in tangible and intangible assets due to investment timing, with spending shifted into H2 2026 in million CHF H1 2025 H1 2026 Cash flow from operating activities before working capital changes adjusted1 125.8 126.7 Working capital changes -43.5 -93.8 Cash flow from operating activities adjusted1 82.4 32.9 Investments in tangible and intangible assets -29.4 -34.4 Cash flow from financial assets -2.5 -3.7 Free cash flow before M&A 50.5 -5.2 Cash flow from M&A2 -34.4 -18.9 Free cash flow 16.1 -24.1
Page 53
Investor Presentation Galenica Group 31.8 15.1 15.4 29.4 12.5 15.9 61.1 27.6 31.3 2025 H1 2025 H1 2026 Investments deferred into H2 2026 53 in % of net sales in million CHF Investments in tangible assets Investments in intangible assets 1.5% 1.4% 1.5% August 2026
Page 54
Investor Presentation Galenica Group Dividend Proposal Board of Directors increased dividend by 8.7% August 2026 54 1.80 2.10 2.20 2.20 2.30 2.50 64.7% 59.7% 69.9% 68.2% 62.8% 66.5% 2020 2021 2022 2023 2024 2025 Dividend per share Payout ratio1 1 Dividend per share in relation to adjusted earnings per share at reporting date
Page 55
Investor Presentation Galenica Group Share information Key figures in CHF Dec 2025 Jun 2026 Share price at reporting date 97.70 84.30 Market capitalisation at reporting date in million CHF 4,867.8 4,198.6 Earnings per share 01/01 – 30/06 from continuing operations1 1.77 1.34 Earnings per share adjusted 01/01 – 30/06 from continuing operations1,2 1.81 1.83 Shareholders’ equity per share at reporting date1 29.73 28.32 1 Attributable to shareholders of Galenica Ltd. 2 For details to the adjusted key figures refer to chapter Alternative performance measures in the Annual Report 2025 August 2026 55
Page 56
Governance
Page 57
Investor Presentation Galenica Group Shareholder structure 50.7% 5.4%3.0% 2.4% 38.2% 0.4% Proportion of shareholders by country (30 Dec 2025) in % Switzerland UK USA ROW SIS Dispos Own shares Major shareholders (31 Dec 2025) − Shareholders over 3%: Shareholders Number of shares Shares in % UBS Fund Management (Switzerland) AG, Switzerland 5,487,581 11.0 Alecta Pensionsförsäkring, Sweden 2,000,000 4.0 BlackRock, Inc., USA 1,579,198 3.2 Swisscanto Fondsleitung AG, Switzerland 1,533,324 3.1 August 2026 57
Page 58
Investor Presentation Galenica Group Overview of our governance structure and instruments − Code of Conduct − Supplier Code of Conduct − Quality Management System (QMS) − Anti-Corruption Policy − Whistleblower Reporting Office − Data Protection Policy − IT Security Policy − Security monitoring system External advisory and inspection bodies / auditors General Meeting Board of Directors Corporate Executive Committee Governance, Nomination and Sustainability Committee (GNSC) Remuneration Committee (RC) Audit and Risk Committee (ARC) Pharmacies Category Man. & Health Services FinanceCEO Products & Home Care Wholesale & Logistics Corporate Communications People & Culture IT & Digital Business Legal & Board Services* Sustainability & PR & Transformation Sustainability Committee Consists of selected EC Members + Corporate Experts and Business Unit Managers Important Policies und management instruments Extended EC Pharmacies Marketing Pharmacies Sales August 2026 58
Page 59
Investor Presentation Galenica Group Board of Directors Dr. Markus R. Neuhaus Chair − Elected since 2019 − Master of law and doctorate in law from the University of Zurich − Vice-Chair of the Board of Directors of Barry Callebaut AG and a member of the Board of Directors of Helvetia Baloise Holding AG and Chair of the Board of Directors of Jacobs Holding AG. He also serves as Vice-Chair of the Board of Trustees of Avenir Suisse. Pascale Bruderer Vice Chair − Elected since 2020 − Masters in political science, University of Zurich − Member of the Board of Directors of TX Group AG and Orell Füssli AG. Since 2019, she has been a member of the Board of Crossiety AG and since 2022, Chair of the Board of Directors of Swiss Stablecoin AG. Elected by the Federal Council, she has served as Vice-President of the ETH Board since 2024. Nadine Balkanyi- Nordmann − Elected since 2025 − Studied law at the University of Zurich and also holds an LL.M. (Master of Laws) from Hong Kong University. − Chair of the Board of Directors of Tele-Check Inter AG since 2017. Since 2021, she has also served as President of the Georg Wittlinger-Stiftung and has been a member of the Board of Directors of Zoo Zurich AG. Bertrand Jungo − Elected since 2018 − Business administrator lic.rer.pol., University of Fribourg − Since 2021, he is the delegate of the Board of Directors of the AG Grand Hotels Engadinerkulm Holding St. Moritz. Furthermore, he is a member of the Board of Neoperl AG/Diaqua AG as well as at Zoologischer Garten Basel AG. Judith Meier − Elected since 2022 − Executive Master of Health Service Administration − Member of the Board of Directors of the Cantonal Hospital of Graubünden; board member of reha andeer ag; a member of “SCIANA The Health Leaders Network“ since 2019 and a member of the Board of Trustees of the Emil-Burkhardt-foundation since 2021 and its Vice President as of 2024. Prof. Dr. med. Solange Peters − Elected since 2023 − Professor, University of Lausanne, head of the department of medical oncology at CHUV − Member of ESMO (European Society for Medical Oncology) for over 10 years, serving as its President for a three-year term. Since 2021, she is President of the International Cancer Foundation (ICF). She is a member of the board of the Swiss Cancer League since 2017 and is its Vice-President since 2023. She also is President of the Swiss Academy of Multidisciplinary Oncology (SAMO) and President of the umbrella Swiss cancer organization Oncosuisse since 2025. Jörg Zulauf − Elected since 2023 − Master of law Attorney-at-law, MBA (UCLA) − Member of the Board of Directors of Maerki Baumann & Co Ltd. and since 2023, he has been Chair of the Board of Directors at SV Group AG. Furthermore, he is a member of the Board of Directors at Innflow AG, Rotkreuz. August 2026 59
Page 60
Investor Presentation Galenica Group Board of Directors1 Committees and competencies ARC (Audit and Risk Committee) Members: Jörg Zulauf (Chairman), Bertrand Jungo, Judith Meier, Nadine Balkanyi-Nordmann Budget / medium-term planning Risk management Compliance / internal audits Acquisitions / investments RC (Remuneration Committee) Members: Bertrand Jungo (Chairman), Pascale Bruderer, Solange Peters Salary policy, remuneration system GNSC (Governance, Nomination & Sustainability Committee) Members: Markus Neuhaus (Chairman), Bertrand Jungo, Pascale Bruderer Nominations, succession planning, HR topics Public affairs, health policy, general conditions ESG / sustainability STI / LTI Non-Financial Reporting 1 The Board of Directors as of 31.12.2025 August 2026 60
Page 61
Investor Presentation Galenica Group Board of Directors1 Competencies and diversity Neuhaus Markus Bruderer Pascale Jungo Bertrand Meier Judith Peters Solange Zulauf Jörg Nadine Balkanyi- Nordmann Industry Experience x x x x x x Digitalisation x x x x Regulations/ Politics x x x x x Leadership/ Big Corp. x x x x x Finance/ M&A x x x Legal/ Compliance x x x HR/ Remuneration x x x x x Sustainability x x x x Competencies 1 The Board of Directors as of 31.12.2025 August 2026 61
Page 62
Investor Presentation Galenica Group Board of Directors1 Competencies and diversity Age of BoD members (December 2025) 46 - 50: 51 - 55: 56 - 60: 61 - 65: 66 - 70:14% 43% 57% Gender of BoD members (December 2025) male female 14% 29% 14% 29% 57% 43% 1 The Board of Directors as of 31.12.2025 August 2026 62
Page 63
Investor Presentation Galenica Group Our organisation August 2026 63
Page 64
Investor Presentation Galenica Group Our Leadership Team August 2026 64 Executive Committee Extended Executive Committee Marc Werner Group CEO Julian Fiessinger Group CFO Andreas Koch Chief Wholesale & Logistics Lukas Ackermann Chief IT & Digital Business Jürg Pauli Chief Sustainability, Public Affairs & Transformation and General Secretary Iris Müller Chief Corporate Communications Arianne Hasler Chief People & Culture Virginie Pache Chief Pharmacies Sales Daniele Madonna Chief Pharmacies Category Management & Health Services Thomas Szuran Chief Products & Home Care; Deputy CEO Cécile Matter Group General Counsel Stephan Mignot Chief Pharmacies Marketing
Page 65
Investor Presentation Galenica Group Remuneration Responsibility for the remuneration process Level of authority CEO Remuneration Committee Board of Directors Annual General Meeting Remuneration policy proposes approves consultative vote on the Remuneration report Performance objectives for short-term bonus and long-term incentive proposes approves Remuneration of members of the Board of Directors proposes approves approves maximum possible remuneration for Board of Directors for the following year Remuneration of the CEO proposes (in consultation with the CBD 1) approves approves maximum possible remuneration for the Corporate Executive Committee including the CEO for the following yearRemuneration of members of the Corporate Executive Committee proposes (in consultation with the CBD 1) approves is informed 1 CBD = Chair of the Board of Directors August 2026 65
Page 66
Investor Presentation Galenica Group Remuneration Remuneration components − The remuneration components of the Corporate Executive Committee (EC) consists of a fixed compensation, benefits and a variable compensation. − The variable remuneration consists of a short-term incentive (STI) and a long- term incentive (LTI). − ESG component: Consists equally out of Net Promoter Score (NPS) and employee motivation rate. − The full LTI and a portion of the STI (32%) is awarded in Galenica shares. Performance measurement: GEP and TSR − Galenica Economic Profit (GEP) is calculated as the Net operating profit after tax (NOPAT) less the average cost of capital (WACC) over the average invested capital. − Relative Total Shareholder Return (TSR) is measured as a percentile ranking against a peer group of relevant companies. The objective is to outperform half of the peer companies (100% payout). 25% annual net sales growth 50% TSR 50% GEP 50% average GEP 25% ESG NOPAT Cost of capital Goal: continuously increasing GEP – = GEPGEP GEP Per year Duration 3 years STI LTI August 2026 66
Page 67
Sustainability
Page 68
Investor Presentation Galenica Group Sustainability at Galenica Overview Company value We increase the value of the company in the long term by having a sustainable impact. Employees We oblige our employees to act responsibly and ensure they have a safe, flexible and supportive working environment. Resource efficiency We use resources sparingly and efficiently and reduce negative environmental impacts. Sustainability principles Sustainable Development Goals (SDGs) The Galenica Group is committed to the SDGs and makes an important contribution to the following objectives in particular: August 2026 68
Page 69
Investor Presentation Galenica Group Sustainability at Galenica Relevance matrix of material topics August 2026 69
Page 70
Investor Presentation Galenica Group Sustainability at Galenica Our sustainability goals August 2026 70 Corporate governance Ethical and legal business activities Protect patient data and IT systems Patients Increase patient and health safety Ensure the availability of medicinal products Employees Promote employee motivation and development Ensure occupational health and safety Retain qualified employees Promote diversity and equal opportunity Environment Committment: to reducing scope 1 & 2 GHG emissions to setting science-based targets of our supplier volume to achieving net zero by 2050
Page 71
Investor Presentation Galenica Group Sustainability at Galenica Our sustainability goals Goal Status Target year Measurement parameter 2023 2024 2025 We raise awareness of compliance issues among our employees at least six times a year, tailored to the respective target group. = Every year Number of measures 4 7 9 We raise awareness of data protection among our employees at least six times a year, tailored to the respective target group. = Every year Number of measures 6 9 12 We make our employees aware of IT security and cybercrime at least six times a year, tailored to the respective target group. = Every year Number of measures 6 11 14 We achieve an annual service level of 99% in the pharma sector. × Every year Service level 98.8% 99.0% 98.6% August 2026 71 realistic → partly delayed / critical critical = achieved ×. not achieved
Page 72
Investor Presentation Galenica Group Sustainability at Galenica Our sustainability goals Goal Status Target year Measurement parameter 2023 2024 2025 We will increase the use of Clinical Decision Support Checks (CDS.CE) to 500 million by 2025 and 1 billion by 2030. 2030 Number of CDS.CE checks (Clinical Decision Support) 278 million 369 million 553 million Customer satisfaction is at the centre of all activities. The satisfaction of end customers is systematically measured by their willingness to recommend us to other (rNPS) and the gap compared to the average of the competition is determined. The ambition is to achieve an rNPS target of 100% every year. × Every year Target achievement rNPS 92.5% target achievement 95.5% target achievement 78.8% target achievement We require our suppliers to comply with the Supplier Code of Conduct and verify this with at least 10 spot checks per year. = Every year Number of spot checks No review 11 12 We will increase the number of healthcare services provided in our pharmacies by 10% each year until 2027 (base year 2023) 2027 Increase in % compared to previous year 14% 32.4% 28.7% August 2026 72 realistic → partly delayed / critical critical = achieved ×. not achieved
Page 73
Investor Presentation Galenica Group Sustainability at Galenica Our sustainability goals Goal Status Target year Measurement parameter 2023 2024 2025 Employee survey "Opinio": The participation rate should be above 75 per cent. The motivation rate between 75 and 80 per cent. = Every year Motivation rate Participation rate 76 / 100 72% 76 / 100 76% 78 / 100 82% We are reducing the time-to-hire by 10% by 2027. (base year 2023 for Pharmacies Sales, 2024 for all other areas) 2027 Time-to-hire Overall: n/a Pharmacies: 63 days Overall: 89 days Pharmacies: 92 days Overall: 63 days (-29%) Pharmacies: 61 days (-3%) We will improve diversity in all units and group companies, keeping the proportion of women in management positions at 50% and increasing the proportion of women in senior management to 33% by 2027. Every year Proportion of female managers (MT) and Senior Management (SMT) 56.6% (MT) 31.2% (SMT) 58.2% (MT) 31.3% (SMT) 59.9% (MT) 31.6% (SMT) We will reduce the incidence of occupational accidents and illnesses (physical and mental) by 10%. (base year 2023) → 2027 Absence rate (comparison of target hours/lost hours) Occupational accidents: 0.09% illnesses: 3.97% Occupational accidents: 0.10% illnesses: 4.05% Occupational accidents:0.1% illnesses: 4.48% August 2026 73 realistic → partly delayed / critical critical = achieved ×. not achieved
Page 74
Investor Presentation Galenica Group Sustainability at Galenica Our sustainability goals Goal Status Target year Measurement parameter 2023 2024 2025 Galenica commits to reduce absolute Scope 1 and 2 GHG emissions 65% by 2035 from a 2023 base year. 2035 tCO2 reduction to base year (marked-based) n/a -21% -27% Galenica also commits that 72% of its suppliers by emissions covering purchased goods and services and upstream transportation and distribution will have science-based targets by 2030. 2030 % supplier commitments n/a n/a 54% August 2026 74 realistic → partly delayed / critical critical = achieved ×. not achieved
Page 75
Investor Presentation Galenica Group ESG Ratings Rating-Agentur Actual Rating Comment ESG Risk − Ranking number 20 among 614 Healthcare companies (Rating of 12.0) − Good scores in Business ethics, Data privacy and security, Governance and Carbon emissions in own operations Absolute Rating Transparency Level − Overall Rating stable − Very strong in Governance, above average in Product safety − Room for improvement in Supply chain management − Score of 8.4/10 − Very strong absolute scoring in the environmental pillar − Very strong relative scoring in the all pillars, especially governance as compared to the industry average LOWNEGL MED HIGH SEVERE DD- D+ C- C C+ BB- B+ A- A A+ Very high BCCC BB BBB A AA AAA (Aug 2025) August 2026 75 (Aug 2026) (March 2026) HighMediumLowVery low
Page 76
Outlook
Page 77
Investor Presentation Galenica Group Market development expectations1 Based on the demographic trends and innovation with many new, high-priced medications, Galenica expects continued strong growth of +/- 5% in the Swiss pharmaceutical market2 in the next years. The strongest growth is expected in the hospital channel. For pharmacies and physicians, Galenica expects pharmaceutical market2 growth of between 3% and 5%, with a stronger growth in the physicians' channel. For the non-medication product ranges3 in pharmacies, we expect a stagnating market development in the next years. These product ranges will continue to face strong competition from other retailers, online and offline. For the sales mix of an average Galenica local pharmacy, excluding high-priced medications, results an expected market growth of between 2% and 4%. 1 Company estimates 2 Medicines Swissmedic lists A, B and D 3 Beauty, personal care, patient care and nutrition August 2026 77
Page 78
Investor Presentation Galenica Group Guidance 2026 August 2026 78 Galenica Group net sales +5% to +7% EBIT adjusted1 +6% to +8% (corresponds +9% to +11% without PY one-off items). The costs associated with the intended closure of Bichsel’s production division will mainly be incurred in the first half of 2026 and are not reflected in the adjusted EBIT1. Dividend for 2026 at least at prior-year level 1 without effects of IAS 19, IFRS 16, IFRS3 and one -off effects, see chapter “Alternative performance measures” of the Annual R eport 2025
Page 79
Investor Presentation Galenica Group Updated mid-term Guidance Galenica expects net sales to grow by 3% to 5% in the next years. Segment Logistics&IT: until 2027, Galenica expects a stable development of its return on sales (ROS)1 due to an intense final phase of the ERP project with a planned migration in H2 2026 and subsequent winddown of the project organization in 2027. Thanks to this investment, Galenica expects significant efficiency gains and an ROS 1 of Logistics&IT to up to 2% in the medium term (2028). Segment Products&Care: with the successful integration of Labor Team and the planned focusing of Bichsel on its homecare business activities, Galenica expects to increase its ROS1 of Products&Care to over 10% in 2027. Galenica aims in its centenary year 2027 to achieve an EBIT2 of CHF 270 million. Galenica continues to aim for net debt2 in the order of +/- 2 × EBITDA2. Galenica continues to pursue a policy of at least stable dividends that grow in line with results. Galenica assumes that the level of CAPEX3 will range between CHF 80-90 million. 1 ROS OS = EBIT adj. / net sales 2 without effects of IAS 19, IFRS 16, IFRS3 and one -off effects, see chapter “Alternative performance measures” of the Annual Report 2025 3 Investments in tangible and intangible assets August 2026 79
Page 80
Investor Presentation Galenica Group Reasons to invest in Galenica Unique combination of defensive resilience and significant growth August 2026 80 Defensive resilience History of growth Highly experienced management team with proven track record … provides investors with potential for upside and attractive cash generation Strategic focus Stable and attractive Swiss healthcare market with favourable long-term fundamentals #1 health and well-being provider with systemic relevance Significant operational advantages from integrated, synergistic and efficient operations Long-term track record of sustainable growth and attractive cash generation Proven strategy to leverage market leadership positions to deliver longer-term upside Strong commitment to strategic initiatives to shape Galenica for the future + +
Page 81
Investor Presentation Galenica Group Galenica Group – Contact information August 2026 81 Investor Relations Julian Fiessinger CFO Tel: +41 58 852 85 31 investors@galenica.com Florian Urech Head of Investor Relations and Corporate Finance Tel: +41 58 852 83 42 investors@galenica.com
Page 82
Investor Presentation Galenica Group Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward- looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. Disclaimer IQVIA The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third-party sources or data. In all cases where historical results are presented or past performance is described, we note that past performance is not a reliable indicator of future results and performance. Copyright ©2026 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries. August 2026 82